Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have earned a consensus rating of “Buy” from the ten ...

Larimar Therapeutics (LRMR) stock rose after Oppenheimer issued an Outperform rating on the company, citing potential for its lead drug nomlabofusp. Read more here.

Fintel reports that on October 16, 2024, Oppenheimer initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a ...

Larimar has undertaken an ongoing open-label extension study of nomlabofusp with the first enrolled patient being dosed in ...

Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans ...

After hours: October 24 at 5:25 PM EDT Loading Chart for LRMR ...

On Wednesday, Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.71 which represents a slight increase of $0.29 or 3.91% from the prior close of $7.42. The stock opened at ...

Fintel reports that on October 2, 2024, HC Wainwright & Co. initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a ...

On Thursday, Larimar Therapeutics (NASDAQ:LRMR) shares received an Outperform rating from Wedbush with a price target set at $22. The biopharmaceutical company, focused on the development of ...